Keywords: sym001, enters, ph, itp, hdn, trial, danish
Sym001 enters Ph I ITP and HDN trial
Article | 19 March 2007
Danish biopharmaceutical firm Symphogen and Sweden's Biovitrum have initiated a Phase I clinical trial of their developmental antibody drug candidate ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
